 Half-Year Review of Inventivas Liquidity Contract with Kepler Cheuvreux Daix France, August 12, 2020 Inventiva Euronext Paris and Nasdaq: IVA, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis NASH, mucopolysaccharidoses MPS and other diseases with significant unmet medical need, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of June 30, 2020: Cash: 995,433.00 Number of shares: 14,361At the last half-year report as of December 31, 2019, the following resources were available in the liquidity account: Cash: 260,756.07 Number of shares: 66,839When the contract was initially implemented, the following resources were included in the liquidity account: Cash: 163,510.42 Number of shares: 34,063 About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH.Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. A Phase III clinical trial in children with MPS VI is currently under preparation following the release of positive results of the Phase IIa clinical trial in adult MPS VI patients at the end of 2019.In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration.The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60 of which are proprietary, as well as a whollyowned research and development facility.Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris Euronext: IVA ISIN: FR0013233012 and on the Nasdaq Global Market in the United States ticker: IVA. ContactsInventiva Frédéric Cren Chairman CEO 33 3 80 44 75 00Brunswick Group Yannick Tetzlaff Tristan Roquet Montegon Aude Lepreux Media relations 33 1 53 96 83 83Westwicke, an ICR Company Patricia L. Bank Investor relations 1 415 513-1284 Important NoticeThis press release contains forward-looking statements, forecasts and estimates with respect to Inventivas clinical trials, clinical trial data releases, clinical development plans and anticipated future activities of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, believes, anticipates, expects, intends, plans, seeks, estimates, may, will and continue and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on managements beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventivas control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, or that candidates will receive the necessary regulatory approvals. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.Please refer to the Universal Registration Document filed with the Autorité des Marchés Financiers on June 19, 2020 under n D.20-0551 for additional information in relation to such factors, risks and uncertainties. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.Attachment Inventiva - PR - Liquidity contract - H1 20 - EN - 12 08 20 